Pulmonary arterial hypertension (PAH) is a rare, severe disease resulting from progressive obliteration of small-caliber pulmonary arteries by proliferating vascular cells. PAH can occur without recognized etiology (idiopathic PAH), be associated with a systemic disease or occur as a heritable form, with BMPR2 mutated in approximately 80% of familial and 15% of idiopathic PAH cases 1-3 . We conducted a genomewide association study (GWAS) based on 2 independent casecontrol studies for idiopathic and familial PAH (without BMPR2 mutations), including a total of 625 cases and 1,525 healthy individuals. We detected a significant association at the CBLN2 locus mapping to 18q22.3, with the risk allele conferring an odds ratio for PAH of 1.97 (1.59-2.45; P = 7.47 × 10 −10 ). CBLN2 is expressed in the lung, and its expression is higher in explanted lungs from individuals with PAH and in endothelial cells cultured from explanted PAH lungs.
The Cochran Q statistical test did not detect any heterogeneity between the ORs obtained for the two cohorts (P = 0.811). The Mantel-Haenszel estimate of common allelic OR derived from the metaanalysis of the results obtained in the two cohorts separately was 1.98 (1.58-2.47), P = 1.65 × 10 −9 .
a P value of the Cochran-Armitage trend test. The P value of the association test in the discovery cohort after controlling for any underlying population stratification (EIGENSTRAT software) was 3.9 × 10 −4 . b Allelic OR calculated from the observed genotype counts.
npg l e t t e r s origin (Online Methods and Supplementary Table 1 ). Application of the EIGENSTRAT program to test for SNP association with idiopathic or familial PAH 7 did not show any evidence of population stratification, with a genomic inflation coefficient of 1.02 ( Supplementary  Fig. 1 ). No SNP achieved the statistical threshold for genome-wide significance (P < 5 × 10 −8 ) (Supplementary Fig. 2 ), but the 384 most significant SNPs with corresponding association P values ranging from 1.82 × 10 −6 to 6.87 × 10 −4 were nevertheless selected for further association testing in an independent replication sample of 285 cases and 457 controls. Of the 384 SNPs genotyped by a dedicated Illumina GoldenGate assay (Online Methods), 319 passed quality control. After Bonferroni correction for the number of tested SNPs, 2 of the 319 SNPs showed significant association with idiopathic and familial PAH (Supplementary Table 2 ), rs2217560 (P = 1.63 × 10 −5 ) and rs9916909 (P = 3.50 × 10 −5 ). These two SNPs are located 52 kb downstream of the CBLN2 gene at 18q22.3 and are in almost complete linkage disequilibrium (r 2 = 0.99).
The association pattern of rs2217560 with idiopathic and familial PAH was homogeneous in both the discovery and replication cohorts ( Table 1 ). In the discovery GWAS, the rs2217560[G] allele was more frequent in cases than in controls (0.123 versus 0.070) and was associated with a higher risk of PAH of 1.87 (1.41-2.48; P = 3.88 × 10 −4 ). In the replication population, the rs2217560[G] allele had a higher frequency in cases than in controls (0.132 versus 0.066), and the corresponding odds ratio (OR) was 2.16 (1.51-3.09; P = 1.63 × 10 −5 ). In the combined sample, the rs2217560[G] allele was associated with a higher risk of PAH of 1.97 (1.59-2.45), with overall statistical significance reaching P = 7.47 × 10 −10 ( Table 1) . No evidence for any sex-specific association was observed (Supplementary Table 3) . We further examined whether the observed association could be explained by untyped SNP(s) located in the vicinity of rs2217560. Using the August 2010 release of the 1000 Genomes Project data set as a reference, we conducted imputation analysis in the GWAS discovery cohort (Online Methods). No single imputed SNP at the 18q22.3 locus showed stronger evidence of association than rs2217560 ( Supplementary Fig. 3 and Supplementary Table 4) . Additional conditional regression analysis of the effect of rs2217560 did not detect any other independent association signal at the CBLN2 locus (Supplementary Table 4) .
Because of the rarity of PAH, it was not possible to collect a larger sample of cases for GWAS analysis, which is the current practice for more common complex diseases 8 . As a consequence, the power of the single discovery sample was rather limited. For example, there was only 35% power to detect an allelic OR of 2.0 for a SNP with a minor allele frequency (MAF) of 0.10 at the genome-wide significance level of 5 × 10 −8 . Accordingly, we used a two-stage GWAS strategy, which provided ~75% power to detect such genetic effects. However, the two-stage strategy did not have enough power to detect moderate genetic effects, with a maximum power of ~25% to detect an OR of 1.5 or less for a SNP with a MAF of 0.20.
The rs2217560 SNP identified through our two-stage GWAS strategy lies 52 kb downstream of the CBLN2 gene. CBLN2 belongs to the cerebellin gene family, which encodes a group of secreted neuronal glycoproteins (CBLN1-CBLN4) and the precursor of CBLN2, a hexadecapeptide with 94% and 44% sequence homology to the CBLN1 and CBLN3 peptides, respectively 9, 10 . CBLN2 has previously been npg l e t t e r s reported to mainly be expressed in different regions of the brain 11 , but, because CBLN2 is in close proximity to the associated SNPs, we assessed CBLN2 expression in the lung and other cell types. We found that CBLN2 mRNA was expressed in the whole lung and, at lower levels, in circulating cells such as lymphocytes. CBLN2 mRNA levels were significantly higher in lungs explanted from individuals with PAH than in histologically normal lung tissue derived from subjects undergoing surgery for lung cancer (control lungs) ( Fig. 1 and Supplementary Fig. 4 ). CBLN2 protein was detected in endothelial, epithelial and circulating cells from subjects with PAH and in control lung samples via immunohistochemistry, but the protein amounts varied widely from sample to sample (Fig. 2) .
In cultured pulmonary vascular cells, we found that CBLN2 mRNA was expressed in endothelial cells isolated from the pulmonary artery (PA-ECs); in contrast, expression was detected at very low levels in pulmonary artery vascular smooth muscle cells (PA-SMCs) (Fig. 3) . CBLN2 mRNA levels in primary cultured endothelial cells explanted from PAH lung samples collected during lung transplantation were higher than in endothelial cells from control lung samples (Fig. 3) . We hypothesized that the CBLN2 synthesized by endothelial cells might act on vascular SMC proliferation in a paracrine fashion. Therefore, we added mature CBLN2 peptide at concentrations ranging from 0.01 to 10 nM 10 to serum-deprived PA-SMCs in primary cultures. A significant log-linear trend for proliferation inhibition was observed in cultured PA-SMCs with increasing concentrations of CBLN2 (Fig. 4) . A generic toxic effect of CBLN2 peptide on PA-SMCs was excluded by measuring the viability of the cells to which CBLN2 was added (Supplementary Fig. 5 ). Preliminary data did not show any evidence for an association between the rs2217560 genotype and CBLN2 mRNA levels in monocytes (data not shown), but these results do not preclude a tissue-specific effect in lungs. CBLN2 was previously shown to bind the S4 domain of neurexin-1β (a presynaptic cell adhesion molecule encoded by NRXN1) as well as the postsynaptic δ2 glutamate receptor (GluD2), contributing to synapse formation by bridging the two molecules 12 . NRXN1, which encodes both neurexin-1α and neurexin-1β, is expressed in the vascular wall. The neurexin-1β isoform, transcribed from an internal promoter and containing a specific N-terminal peptide absent in the neurexin-1α isoform, is present in a subset of SMCs and also in chicken embryonic arteries 13 . Our results show that the neurexin-1β transcript is expressed in the lung, without there being a significant difference between control and PAH lung samples ( Supplementary  Fig. 6 ). Antibody to neurexin-1β was shown to decrease fibroblast growth factor 2 (FGF2)-induced angiogenesis in the chorioallantoic membrane chicken model and to decrease noradrenaline-induced vessel tension in isolated chicken embryonic arteries 13 . In recent years, several molecules have been implicated in both neurogenesis and angiogenesis 14 .
Altogether, these results strongly support a role for the CBLN2 locus as a new contributor to the physiopathology of idiopathic and familial PAH. The CBLN2 gene is a promising candidate because of its vascular expression and its effects in vascular cells. CBLN2, which we find to be produced by endothelial cells, was previously shown to bind an adhesion molecule present in SMCs. Further studies are needed to document the putative function of CBLN2 in pulmonary vessels.
In conclusion, we report the first GWAS of idiopathic and familial PAH negative for BMPR2 mutation, which identified an allele associated with twofold greater risk of the disease. The associated locus is new with respect to PAH pathogenesis. Fine mapping and deep sequencing of the entire locus is now required to identify and characterize the functional variant(s) responsible for the observed association. These results pave the way for improved understanding of pathophysiology as well as new therapeutic approaches for PAH. Figure 4 Cell proliferation in PA-SMCs treated with CBLN2. Cell proliferation was measured by BrdU incorporation in PA-SMCs cultured in complete medium (5% FCS) or serum-depleted medium (0.2% FCS) to which CBLN2 peptide was added at concentrations ranging from 0 to 10 nM. A significant decrease in the proliferation of PA-SMCs (P = 6.33 × 10 −4 on a log-linear scale) was observed when cells were exposed to increasing doses of CBLN2 peptide. Each symbol represents the value for one experiment, shown together with the fitted log-linear regression line.
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Study population. Diagnosis with PAH was defined by hemodynamic measurement during right-heart catheterization for all cases included in the study (discovery stage and replication stage), including those identified by the French PAH Network between 1 January, 2003, and 1 April, 2010. For all cases, PAH was defined as a mean pulmonary arterial pressure equal to or exceeding 25 mm Hg associated with normal pulmonary capillary wedge pressure. Hemodynamic evaluation by right-heart catheterization was performed at baseline in all subjects according to previously described protocols 15, 16 . PAH was considered to be idiopathic after clinical and biological investigations eliminated all known causes. Cases with idiopathic PAH were screened for BMPR2 mutations, and cases with a family history of PAH were screened for BMPR2 and ACVRL1 mutations. Screening for point mutations and large chromosomal rearrangements was performed as previously reported 2, 17 . Familial cases carrying a mutation in either of these genes were excluded. When cases had a family history of PAH without evidence of either BMPR2 or ACVRL1 mutation, a single index case from the family was included in the GWAS analysis.
In the discovery stage, a total of 378 cases meeting these criteria were included. All clinical characteristics at PAH diagnosis and follow-up were stored in the Registry of the French PAH Network 6 . This registry was set up in agreement with French bioethics laws (French Commission Nationale de l'Informatique et des Libertés) and with informed consent from participants 2 . The control group was composed of a random sample of 1,140 subjects who were free of any chronic disease from the 3C Study 18 . The 3C Study is a population-based prospective cohort with a 4-year follow-up carried out in three French cities: Bordeaux (southwest France), Montpellier (southeast France) and Dijon (central eastern France). This study has served as a control population for several French GWAS projects [19] [20] [21] [22] .
In the replication stage, specimens (297 PAH cases and 479 healthy controls) from participants in the Vanderbilt Prospective Pulmonary Hypertension Research Cohort study and from the Columbia University Pulmonary Hypertension Center were included. These subjects were recruited via the Vanderbilt and Columbia Pulmonary Hypertension Centers and the NIH Clinical Trials website and in collaboration with the Pulmonary Hypertension Association Conference Research Recruitment Room (2010 Conference, Anaheim, California). The Vanderbilt University Medical Center and the Columbia University Institutional Review Boards approved all study protocols. All participants gave informed written consent to participate in genetic and clinical studies and underwent genetic counseling, when appropriate, in accordance with the guidelines of the American College of Chest Physicians 23 .
As in the discovery stage, PAH was defined by a mean pulmonary arterial pressure equal to or exceeding 25 mm Hg associated with normal pulmonary capillary wedge pressure. Hemodynamic evaluation by right-heart catheterization was performed at baseline in all subjects according to previously described protocols 15, 16 . PAH was considered to be idiopathic, after clinical and biological investigations eliminated all known causes, or familial, as appropriate. Screening for mutations in BMPR2 and ACVRL1 was the same as for the discovery stage.
Genotyping. In the discovery stage, the sample of 378 idiopathic or familial PAH cases and 1,140 healthy controls were typed with the Illumina Human610-Quad BeadChip. Individuals with genotyping success rates lower than 95% were excluded from the analysis, as were individuals showing close relatedness. The latter individuals were assessed by pairwise identity clustering by state distance (IBS) and multidimensional scaling (MDS) using PLINK software 24 . The EIGENSTRAT program 7 was further used to detect individuals of nonEuropean ancestry. A total of 104 subjects (32 cases and 72 healthy controls) were thus excluded from the analysis because of close relatedness and/or evidence of non-European ancestry. SNPs showing significant (P < 1 × 10 −5 ) deviation from Hardy-Weinberg equilibrium (HWE) in controls, MAF of <1% in controls or <5% in cases, or genotyping call rate of <99% were filtered out. This resulted in a final analysis of 462,499 autosomal and 9,922 X-linked SNPs in a sample of 340 PAH cases and 1,068 healthy controls.
In the replication stage, the 384 SNPs showing the strongest association with PAH and assigned an Illumina ScoreDesign greater than 0.4 were selected for genotyping in an independent sample of 297 idiopathic or familial PAH cases and 479 controls using the Illumina GoldenGate assay. A total of 34 individuals (12 cases and 22 controls) were discarded owing to low genotype calling rates (<80%). SNPs showing significant (P < 1 × 10 −5 ) deviation from HWE in controls or call rates of <99% were removed from the analysis, resulting in the statistical analysis of 319 SNPs in a sample of 285 cases and 457 controls.
Statistical analysis.
At the discovery stage, the genome-wide association analysis of SNPs was conducted using the EIGENSTRAT program that corrects for any uncontrolled population stratification 7 . The genomic control inflation factor was also computed according to the median test statistic 25 . At the replication stage, the association of SNPs with PAH was assessed by use of the Cochran-Armitage trend test 26 . Homogeneity of associations across the two stages was tested using the Mantel-Haenszel method 27 .
The imputation of 11,572,501 autosomal SNPs was conducted using MACH and Minimac software according to the August 2010 release of the 1000 Genomes Project CEU reference data set (Utah residents of Northern and Western European ancestry). The association of each imputed SNP with PAH was tested by logistic regression analysis in which allele dosage (0, 1 or 2 copies of the minor allele) for imputed SNPs was assessed. Analyses were adjusted for the first four principal components and were performed using mach2dat (v 1.08.18) software.
RT-PCR expression studies.
To study CBLN2 expression in pulmonary vascular cells, lung specimens were obtained at the time of lung transplantation from individuals with idiopathic PAH. Control lung specimens were obtained from subjects without any evidence of pulmonary vascular disease who underwent lobectomy or pneumonectomy for localized lung cancer, with normal tissue collected at a distance from the tumors. Both control and PAH lung specimens were collected under the same conditions by the same surgical department (Supplementary Table 5 ). This study was approved by the local ethics committee (Comité de Protection des Personnes Ile-de-France, Le Kremlin-Bicêtre, France), and participants gave informed consent before the study. For RNA extraction, lung samples were washed in PBS and then immediately frozen in liquid nitrogen and stored at −80 °C. Subsequently, PA-ECs and PA-SMCs were isolated from idiopathic PAH and control lung samples (Supplementary Table 5 ) and cultured as previously described 28, 29 . Cells were used from passages 3-6. RT-PCR assays were performed as previously described 30 using the primers listed in Supplementary Table 6 . Data are expressed as mean fold change ± s.d. from at least three independent experiments. Statistical analysis was performed using a non-parametric Mann-Whitney U test for single comparisons and ANOVA for multiple comparisons (XLSTAT software, Addinsoft). P values less than 0.05 were considered to be significant.
Immunohistochemical studies. Lung sections were stained and analyzed as described 31 . Immunohistochemical analysis was performed on formalin-fixed samples. Paraffin-embedded sections were stained with polyclonal rabbit primary antibody against human CBLN2 (Abgent, AP11835b; 1:200 dilution). Biotinylated secondary antibody to rabbit IgG (Vector, BA-1000) was used for the detection of primary antibody, and Vector Red alkaline phosphatase substrate (Vector, Sk-5100) was the chromogen.
Proliferation assays. PA-SMCs purchased from Lonza were seeded in SmGM-2 BulletKit medium (Lonza) at a density of 5,000 cells per well in 96-well plates. The following day, cells were starved in SmGM-2 medium with 0.2% FCS for 24 h before being stimulated with the CBLN2 peptide (SGSAKVAFSATRSTNH; ProteoGenix) at concentrations of 0.01, 0.1, 1 and 10 nM. After 24 h of incubation with the CBLN2 peptide, proliferation was measured by a BrdU incorporation assay using a BrdU cell proliferation ELISA kit (Roche Diagnostics) according to the manufacturer's instructions. Statistical analysis was performed using a log-linear regression test. 
